Use of Topical Corticosteroids in the Treatment of Noninfectious Inflammatory Dermatoses of the Scalp: A Survey of Practicing Dermatologists and Dermatology Residents Using Delphi Methodology

DOI: https://doi.org/10.2147/ccid.s448016

2024-03-18

Clinical Cosmetic and Investigational Dermatology

Abstract:Juan Francisco Mir-Bonafé, 1 Jaime Piquero-Casals, 2 Ludmila Prudkin, 3 Jesus Delgado, 3 Julia Santamaria Martínez, 3 Vicente Garcia-Patos Briones 4 1 Department of Dermatology, Hospital Son Llàtzer, Palma de Mallorca, Spain; 2 Department of Aesthetic Dermatology and Laser, Dermik, Clínica Dermatológica Multidisciplinar, Barcelona, Spain; 3 Innovation and Development, ISDIN, Barcelona, Spain; 4 Department of Dermatology, Hospital Vall d'Hebron, Barcelona, Spain Correspondence: Jaime Piquero-Casals, Department of Aesthetic Dermatology and Laser, Dermik, Clínica Dermatológica Multidisciplinar, Barcelona, Spain, Tel +34 935464710, Email Background: Noninfectious inflammatory dermatoses of the scalp are common, and their symptomsin particular, those affecting appearance, can have a psychological effect that may be disproportionate to their clinical severity. Effective, cosmetically acceptable treatments are important to manage these conditions. Topical corticosteroids form the cornerstone of acute treatment for many of these conditions. We surveyed practicing dermatologists and dermatology residents to determine the current clinical practice in prescribing topical corticosteroids for these disorders in their various preparation formats. Methods: A Delphi method was used, consisting of 2 questionnaire rounds. The first round contained 34 questions and was completed by 612 dermatologists and dermatology residents via email. The first round of responses was analyzed, and points that had > 70% agreement were used to form a second questionnaire of 21 statements. This second round was completed by 346 participants, and their responses were used to generate a final report. Participants were practicing in both public and private practices. Results: Clobetasol propionate 0.05% topical solution was considered to be the most appropriate treatment for noninfectious inflammatory scalp dermatoses in general, with 75.1% agreement in the second round of questionnaire. The main advantages of clobetasol propionate over other topical corticosteroids were reported as potency, effectiveness, and broad action spectrum (94.8% agreement). The preferred pharmaceutical format was the solution of clobetasol propionate. Conclusion: Clobetasol propionate was the preferred topical treatment for the management of scalp dermatoses, usually as first-line treatment; solution was the preferred preparation. Keywords: seborrheic dermatitis, psoriasis, shampoo, topical, solution, clobetasol, scalp, therapy Noninfectious inflammatory dermatoses of the scalp include seborrheic dermatitis, eczema, psoriasis, lichen planopilaris (and the variant frontal fibrosing alopecia), alopecia areata, neurodermatitis (aka lichen simplex chronicus), and discoid lupus erythematosus. Many of these share common or overlapping symptoms, 1 and can have a considerable impact on quality of life. In addition to itch, which can be highly distressing, there are the emotional and social consequences of symptoms such as scaling, flaking, and possibly hair-loss, in a very visible area. Topical corticosteroid-based preparations, which inhibit epidermal proliferation and inflammation and modulate immune response, 2 form the cornerstone of treatment for many scalp dermatoses. 3,4 The formulation of topical treatments for the scalp is of utmost importance: 5 the visibility of the area and presence of hair make cosmesis key, and formats including foam, gel, solution, shampoo, and spray have been developed over the years, which are often preferable to ointments or creams. 3 Delivery of therapy can also represent a challenge 3 as medicated shampoos are only in contact with the affected areas for a very short time. 3 Clobetasol propionate is a class I very potent steroid that is widely used, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. 6 Its formulation as a 0.05% scalp application is safe and effective treatment. 7 Although topical corticosteroids are widely used and also well established as safe and effective treatments, professional dermatological associations have noted "great variability in aspects such as dosing, potency and application quantity". 8 While individualized treatment is important, we sought to establish a picture of current practice among dermatologists in the treatment of scalp dermatoses, particularly regarding use of topical corticosteroids in their various preparations/formulations. A Delphi method was used; this method is based on a series of "rounds", with analysis of the responses provided as feedback to the parti -Abstract Truncated-

dermatology